The Moving Average Convergence Divergence (MACD) for QTTB turned positive on October 08, 2026. Looking at past instances where QTTB's MACD turned positive, the stock continued to rise in 36 of 38 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QTTB's RSI Oscillator exited the oversold zone, 22 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 212 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for QTTB entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.423) is normal, around the industry mean (2.978). P/E Ratio (2.745) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLXN declined for three days, in 184 of 201 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLXN as a result. In 28 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 42%.
The Aroon Indicator for SLXN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +43.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLXN advanced for three days, in 53 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
SLXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.436) is normal, around the industry mean (3.009). P/E Ratio (-0.008) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SLXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
QTTB | ||
|---|---|---|
OUTLOOK RATING 1..100 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 16 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 35 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| QTTB | SLXN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 1 day ago 75% |
| Stochastic ODDS (%) | 2 days ago 87% | 1 day ago 62% |
| Momentum ODDS (%) | N/A | 1 day ago 42% |
| MACD ODDS (%) | 2 days ago 90% | N/A |
| TrendWeek ODDS (%) | 2 days ago 86% | 1 day ago 70% |
| TrendMonth ODDS (%) | 2 days ago 88% | 1 day ago 80% |
| Advances ODDS (%) | 9 days ago 87% | about 1 month ago 56% |
| Declines ODDS (%) | 5 days ago 88% | 7 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 1 day ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 1 day ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
QTTB’s FA Score shows that 1 FA rating(s) are green while SLXN’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
QTTB’s TA Score shows that 5 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).
QTTB (@Biotechnology) experienced а +6.95% price change this week, while SLXN (@Biotechnology) price change was -12.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
QTTB is expected to report earnings on Nov 05, 2026.
SLXN is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, QTTB has been loosely correlated with CLRB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if QTTB jumps, then CLRB could also see price increases.
| Ticker / NAME | Correlation To QTTB | 1D Price Change % | ||
|---|---|---|---|---|
| QTTB | 100% | +10.65% | ||
| CLRB - QTTB | 62% Loosely correlated | +9.82% | ||
| MESO - QTTB | 51% Loosely correlated | +3.85% | ||
| STOK - QTTB | 49% Loosely correlated | +7.21% | ||
| IBRX - QTTB | 40% Loosely correlated | +4.16% | ||
| ANAB - QTTB | 39% Loosely correlated | -7.74% | ||
More | ||||